Post on 03-Apr-2018
7/28/2019 Kidney Transplantation in Sensitized Individual
1/32
ATUL DESAI
19/3/12
7/28/2019 Kidney Transplantation in Sensitized Individual
2/32
Transplantation in HLA sensitized individuals or in ABO
incompatible individuals was contraindicated earlier.
Because of hyperacute rejection or early antibody mediated
rejection.
However, with currently available immunosuppressive
medications & advancement in understanding of AMR,
transplantation in such individuals is possible.
7/28/2019 Kidney Transplantation in Sensitized Individual
3/32
Sensitized
individual or ABOI
Cadavertransplant wait
list
Living donortransplantation
Paireddonation
Desnesitize
& +veCM TX
7/28/2019 Kidney Transplantation in Sensitized Individual
4/32
CC
Abdetection
cytotoxicty
Flowcytometry
Solidphaseassay
7/28/2019 Kidney Transplantation in Sensitized Individual
5/32
Complement dependent lymphocytotoxicity-CDC. : recipient
serum incubated with B cells and T cells from pool of donors.
Complement is added and cell lysis is noted.
Anti human globulin enhanced cytotoxicity: anti humanglobulin is added.
Sensitive, detects low titer and non cytotoxic antibodies
7/28/2019 Kidney Transplantation in Sensitized Individual
6/32
Even more sensitive antibody assay.
A mixture of target cells composed of lymphocytes from 5-10
donors is used.
Pts serum is mixed with target cells.
Washed and incubated with monoclonal mouse anti CD3 &
CD19/CD20 antibodies.
These antibodies will be conjugated with fluoroscent dyes.
T cells stain red-orange & B cells stain red color, detected by
flow cytometer.
7/28/2019 Kidney Transplantation in Sensitized Individual
7/32
7/28/2019 Kidney Transplantation in Sensitized Individual
8/32
7/28/2019 Kidney Transplantation in Sensitized Individual
9/32
HLA sensitization is not a contraindication for transpalntation.
It represents pts at IMMUNOLOGICAL RISK.
Immunological risk for hyperacute rejection if DSA are very
high, or acute AMR if DSA are low.
NO increased risk in pts with very low level.
7/28/2019 Kidney Transplantation in Sensitized Individual
10/32
Therefore it is important to asses the level of DSA.
All the tests to detect alloantibodies are qualitative.
However,the level of DSA can be semiquantitatively assessed
using various crossmatch assays.
Serial dilutions in cytotoxicity assay.
Channel shift in FXM
7/28/2019 Kidney Transplantation in Sensitized Individual
11/32
Cadaver donor list: if the pt has no living donor.
US data: In the United States, approximately 15,000 patients
on the Organ Procurement and Transplantation Network
(OPTN)/
United Network for Organ Sharing (UNOS) cadaver donor
kidney waiting list are sensitized.
7/28/2019 Kidney Transplantation in Sensitized Individual
12/32
15000
8000 havehigh PRA
>80%
7/28/2019 Kidney Transplantation in Sensitized Individual
13/32
Desensitization prior to cadaver Tx: IVIG or rituximab used.
Plasmapheresis: requires coordination with Tx surgery date.
Hence can not be used in cadaver tx.
7/28/2019 Kidney Transplantation in Sensitized Individual
14/32
In a multicenter, double-blinded study, 101 sensitized renalallograft candidates received high-dose IVIG (2 g/kg monthly 4) or equivalent volume placebo.
Baseline PRA levels as determined by a T cell cytotoxicity assaywere similar in both groups (80% in both).
IVIG treatment decreased the PRA by approximately 10% by 4months, but the PRA returned to baseline at 6 months (2 monthsafter the last IVIG infusion) and was equal to that of placebo-treated patients at that time point.
Among dose-adherent patients, 35% (n = 16) IVIG and 17% (n = 8) placebo patients were able to be transplanted. Nine of 17 patients transplanted after IVIG infusion had a
rejection episode, however, compared with only 1 of10 placebo-treated patients.
7/28/2019 Kidney Transplantation in Sensitized Individual
15/32
D
R
D
R
7/28/2019 Kidney Transplantation in Sensitized Individual
16/32
An increasingly viable option for sensitized candidates with anotherwise suitable living donor is to perform the transplant
despite the presence of a positive crossmatch.
Treatment protocol depends on the level of DSA in recipient.
High titers of DSA require desensitization prior to Tx.
Low levels need no desensitization, needs careful post Tx
monitoring.
7/28/2019 Kidney Transplantation in Sensitized Individual
17/32
Need to be desensitized.
The DSA levels need to be reduced prior to Tx
Goal should be to achieve a negative cytotoxicity crossmatch
at the time of transplantation.
2 major approaches : high dose IVIG and plasmapheresis.
7/28/2019 Kidney Transplantation in Sensitized Individual
18/32
IVIG 2g/kg body wt (max of 140 g)
successful in ameliorating a positive complement-dependent
cytotoxicity crossmatch and permitting successful
transplantation
Patients who fail to respond to one dose of IVIG may respond
subsequently to repeated doses.
7/28/2019 Kidney Transplantation in Sensitized Individual
19/32
The likelihood of an individual responding to high-dose IVIGtherapy may be predicted by performing an in vitro
crossmatch after adding IVIG to the sera to be studied. A
decrease or blockade of the crossmatch suggests that the
patient would respond in vivo after administration of IVIG.
7/28/2019 Kidney Transplantation in Sensitized Individual
20/32
the goal of plasmapheresis is to remove DSA physically beforetransplantation and obtain a negative crossmatch at the time of
transplantation.
IVIG usually is given in conjunction with plasmapheresis at a
lower dose of IVIG (typically 5 to 10 g based on body weight)than that used when IVIG is given alone for desensitization.
7/28/2019 Kidney Transplantation in Sensitized Individual
21/32
IVIG in this approach is given to preventhypogammaglobulinemia associated with multiple
plasmaphereses, although it is possible that it provides some of
the immunomodulatory effect
7/28/2019 Kidney Transplantation in Sensitized Individual
22/32
Stegall MD, Gloor JM, Waters J, et al: A comparsion of plasmapheresis vs highdose IVIG desensitization in renal allograft recipients
with high levels of donor specific alloantibody. Am J Transplant 6:348, 2006
7/28/2019 Kidney Transplantation in Sensitized Individual
23/32
Induction : IL2 receptor antagonist or rabbit ATG
Maintainanace: TAC, MMF, steroid
7/28/2019 Kidney Transplantation in Sensitized Individual
24/32
Hyperacute rejection is very low.
No need of desensitization in them.
However they are at increased risk of early AMR.
7/28/2019 Kidney Transplantation in Sensitized Individual
25/32
7/28/2019 Kidney Transplantation in Sensitized Individual
26/32
Reason for AMR in pts with low DSA: result of anamnesticmemory response produced by reexposure of recipient
memory B cells to circulating donor antigen.
Need to prevent memory bcell response.
Induction: ATG, IVIG +/- rituximab.
7/28/2019 Kidney Transplantation in Sensitized Individual
27/32
7/28/2019 Kidney Transplantation in Sensitized Individual
28/32
7/28/2019 Kidney Transplantation in Sensitized Individual
29/32
Monitor DSA.
Aim to keep T cell & B cell channel shift < 300 in the first 2
weeks post Tx.
May need additional IVIG or plasmapheresis in post Tx
period.
7/28/2019 Kidney Transplantation in Sensitized Individual
30/32
Acute humoral rejection is rare beyond 2 months aftertransplantation in ABO-incompatible and positive-crossmatch
kidney transplant recipients.
Generally, antidonor antibody is lower at this point after
transplantation and is well tolerated by the allograft. Graft survival rates of positive-crossmatch kidney transplants
have been good. Reported 1-year graft survival rates have
been approximately 80%
7/28/2019 Kidney Transplantation in Sensitized Individual
31/32
7/28/2019 Kidney Transplantation in Sensitized Individual
32/32
Sensitized
individual or ABOI
Cadavertransplant wait
list
Living donortransplantation
Paireddonation
Desnesitize
& A2 toB/O tx